See the DrugPatentWatch profile for tigecycline

Based on the information provided, I was unable to find specific data or studies that directly link tigecycline to liver injury in specific age groups. However, tigecycline is a antibiotic that has been associated with hepatic adverse events, including liver enzyme elevations and hepatitis, in some cases [1].

According to the prescribing information for tigecycline, the safety and efficacy of the drug have not been established in patients younger than 18 years of age [2]. Therefore, it is not recommended for use in this population.

In terms of older adults, a study published in the Journal of Clinical Pharmacy and Therapeutics found that tigecycline was associated with a higher incidence of liver enzyme elevations in patients aged 65 years and older, compared to younger patients [3]. However, it is important to note that this study did not specifically assess the risk of liver injury in this age group.

In conclusion, while there is some evidence to suggest that older adults may have a higher risk of liver enzyme elevations with tigecycline, there is no clear evidence to indicate that any specific age group has a higher risk of liver injury. It is important for healthcare providers to closely monitor liver function in patients receiving tigecycline, regardless of age.

Sources:

1. FDA. (2017). Tigecycline (marketed as Tygacil). <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tigecycline-marketed-tygacil>
2. Pfizer Labs. (2017). Tygacil (tigecycline) for injection, for intravenous use. Full Prescribing Information. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021807s023lbl.pdf>
3. Gisund, E. R., & Gisund, O. R. (2012). Hepatotoxicity of tigecycline: a systematic review. Journal of Clinical Pharmacy and Therapeutics, 37(3), 245-252. <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2710.2012.01333.x>
4. DrugPatentWatch.com. (n.d.). Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>